5437W-13: Exelixis HCC

CRC 13091: A Phase III, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib

Type of Study
Cancer (Oncology) - Liver
Swedish Cancer Institute
Short Description
Purpose: The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with placebo on overall survival in subjects with advanced hepatocellular carcinoma who have received prior sorafenib.
Open to Enrollment
Principal Investigator
Philip Gold, M.D.
Eligibility Notes
  • Histological or cytological diagnosis of HCC.
  • The subject has disease that is not amenable to a curative treatment approach.
  • Received prior sorafenib.
  • Progression following at least 1 prior systemic treatment for HCC.
  • ECOG performance status of 0 or 1.
  • Child-Pugh Score of A.
  • No fibrolamellar carcinoma or mixed hepatocellular cholangiocarcinoma
  • No more than 2 prior systemic therapies for advanced HCC
  • No prior cabozantinib treatment
  • No radiation therapy within 4 weeks (2 weeks for radiation for bone metastases) or radionuclide treatment within 6 weeks of randomization
More Info Link
Additional information about the study summary and eligibility criteria may be viewed on the U.S. National Institutes of Health (NIH) website.
(206) 215-3086